Home Drug IndexClinical Monograph

Alprazolam Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Navigation

Therapeutic Class

Anxiolytic

Subclass

Psychiatry

Schedule (India)

Schedule H

Routes

Oral, Sublingual

Formulations

Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Sublingual tablets: 0.25 mg, 0.5 mg
Extended-release tablets: 0.5 mg, 1 mg, 2 mg (limited availability)

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Generalised Anxiety Disorder (GAD)

Parameter	Dose
Starting dose	0.25–0.5 mg orally twice to three times daily
Titration	Increase by 0.25–0.5 mg every 3–4 days based on clinical response
Usual maintenance dose	0.5–4 mg/day in divided doses (2–3 times daily)
Maximum dose	4 mg/day

Clinical Notes:

Use lowest effective dose for shortest possible duration
Short-acting agent; monitor for breakthrough anxiety between doses
Taper gradually when discontinuing (reduce by 0.25–0.5 mg every 3 days)
Not first-line for chronic anxiety — prefer SSRIs for long-term management
Reassess need for continuation every 2–4 weeks

2. Panic Disorder (With or Without Agoraphobia)

Parameter	Dose
Starting dose	0.5 mg orally three times daily (OR 0.5–1 mg/day in divided doses)
Titration	Increase by 0.5–1 mg/day every 3–4 days based on response and tolerability
Usual maintenance dose	2–6 mg/day in divided doses
Maximum dose	10 mg/day (specialist psychiatry supervision required)

Clinical Notes:

Higher doses often required compared to GAD
Extended-release formulation may improve compliance and reduce interdose rebound
Doses >6 mg/day require specialist psychiatric evaluation
Combine with cognitive behavioural therapy for optimal outcomes
Avoid abrupt discontinuation — high risk of rebound panic and withdrawal seizures

Secondary Indications – Adults (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Pre-procedural / Situational Anxiety (OFF-LABEL)	0.25–0.5 mg once or twice daily	1–3 days only	Not required for short-term	Indian hospital protocols; pragmatic use
Adjunctive Therapy in Treatment-Resistant Depression with Anxiety Features (OFF-LABEL)	0.25–0.5 mg two to three times daily	Short-term only (2–4 weeks maximum)	Specialist only (Psychiatrist)	Limited evidence; Indian psychiatric practice consensus
Acute Alcohol Withdrawal — Mild to Moderate (OFF-LABEL)	0.5–1 mg three to four times daily	3–7 days with tapering	Specialist only	Indian de-addiction centre protocols; not first-line (prefer diazepam/lorazepam)

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

⚠️ Not routinely recommended in patients under 18 years of age. Use only under specialist paediatric psychiatry supervision.

Primary Indications

Not applicable — no approved paediatric indications in India.

Secondary Indications – Paediatrics (Off-label)

Indication	Age	Dose	Duration	Supervision	Evidence Basis
Severe Refractory Anxiety Disorder (OFF-LABEL)	≥12 years only	0.005–0.02 mg/kg/day in 2–3 divided doses; titrate cautiously up to 0.06 mg/kg/day	Short-term only (maximum 2–4 weeks)	Specialist only (Child Psychiatrist)	Limited evidence; Indian specialist psychiatric practice

Safety Monitoring:

Sedation level, paradoxical reactions (agitation, aggression)
Behavioural changes, cognitive impairment
Signs of dependence

Age Restriction:

Avoid below 12 years of age except under exceptional circumstances with specialist child psychiatry supervision
Not recommended below 6 years under any circumstances

Renal Adjustments

Renal Function	Recommendation
Mild to Moderate Impairment	No dose adjustment required
Severe Impairment (eGFR <30)	Use with caution; start at lower end of dosing range; increased CNS sensitivity possible
Dialysis	Not significantly removed by haemodialysis; no supplemental dose required

Hepatic adjustment

Contraindications

Known hypersensitivity to alprazolam or other benzodiazepines
Acute narrow-angle glaucoma
Concurrent use with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, cobicistat)
Severe respiratory insufficiency or respiratory depression
Acute pulmonary insufficiency
Myasthenia gravis
Sleep apnoea syndrome (severe/uncontrolled)
Severe hepatic impairment

Cautions

Elderly or debilitated patients (increased sensitivity, fall risk)
History of substance use disorder or alcohol dependence (high dependence potential)
Mild to moderate sleep apnoea
Chronic obstructive pulmonary disease
Hepatic impairment (mild to moderate)
History of depression or suicidal ideation
Concurrent use with other CNS depressants
Patients requiring prolonged treatment (dependence risk)
History of paradoxical reactions to benzodiazepines
Patients operating machinery or driving

Pregnancy

Parameter	Information
Overall Safety	Avoid unless clearly necessary; associated with increased risk of congenital malformations (first trimester) and neonatal complications
Risk	Floppy infant syndrome, neonatal withdrawal, respiratory depression if used near term
Preferred Alternatives	SSRIs (sertraline, escitalopram) under obstetric-psychiatric supervision for chronic anxiety
When Use May Be Justified	Acute, short-term use for severe anxiety when non-pharmacological and SSRI options have failed; joint obstetric-psychiatry decision
Monitoring	Fetal growth, neonatal sedation, withdrawal symptoms after birth; avoid doses >2 mg/day near term

Lactation

Parameter	Information
Compatibility	Not recommended for chronic use during breastfeeding
Expected Drug Level in Milk	Low to moderate
Risk to Infant	Sedation, poor feeding, weight loss, withdrawal symptoms with chronic exposure
Preferred Alternatives	Sertraline or escitalopram (if antidepressant/anxiolytic needed)
If Short-term Use Essential	Avoid breastfeeding for 4–6 hours after each dose; monitor infant closely
Infant Monitoring	Sedation, feeding difficulties, weight gain, alertness

Elderly

Parameter	Recommendation
Starting dose	0.25 mg once or twice daily
Titration	Increase by no more than 0.25 mg every 5–7 days
Maximum recommended	2 mg/day (lower than general adult maximum)
Increased Risks	Falls, fractures, oversedation, cognitive impairment, paradoxical reactions, delirium
Additional Precautions	Avoid long-term use; consider safer alternatives (SSRIs, buspirone) for chronic anxiety; regular reassessment mandatory

Major drug interactions

Interacting Drug	Mechanism	Effect	Management
Ketoconazole, Itraconazole	Strong CYP3A4 inhibition	Markedly increased alprazolam levels; severe sedation risk	Contraindicated — avoid combination
Ritonavir, Cobicistat	Strong CYP3A4 inhibition	Significantly increased alprazolam exposure	Contraindicated — avoid combination
Opioids (morphine, tramadol, fentanyl)	Additive CNS depression	Profound sedation, respiratory depression, coma, death	Avoid if possible; if essential, reduce doses of both and monitor closely
Alcohol	Additive CNS depression	Severe sedation, respiratory depression, psychomotor impairment	Avoid concurrent use; counsel patient
Fluvoxamine	CYP3A4 inhibition	Increased alprazolam levels (2–3 fold)	Reduce alprazolam dose by 50%; monitor closely

Moderate drug interactions

Interacting Drug	Effect	Management
Clarithromycin, Erythromycin	Moderate CYP3A4 inhibition; increased alprazolam levels	Monitor for increased sedation; consider dose reduction
Fluconazole	Moderate CYP3A4 inhibition	Monitor clinical response; may need dose adjustment
Carbamazepine, Phenytoin	CYP3A4 induction; reduced alprazolam efficacy	May need higher alprazolam doses; monitor for breakthrough anxiety
Rifampicin	Strong CYP3A4 induction	Significantly reduced alprazolam efficacy
Theophylline	May antagonise sedative effect	Monitor for reduced anxiolytic efficacy
Digoxin	Possible increased digoxin levels (especially in elderly)	Monitor digoxin levels in elderly patients
Cimetidine	Inhibits hepatic metabolism	Monitor for increased sedation
Other CNS depressants (antihistamines, antipsychotics)	Additive sedation	Use with caution; monitor for oversedation

Common Adverse effects

Drowsiness, sedation
Fatigue, lethargy
Dizziness, lightheadedness
Impaired coordination, ataxia
Memory impairment, anterograde amnesia
Dry mouth
Headache
Blurred vision
Constipation
Changes in libido

Serious Adverse effects'

Adverse Effect	Clinical Action
Physical dependence and withdrawal syndrome (anxiety, insomnia, tremors, seizures)	Taper gradually over weeks; never discontinue abruptly after prolonged use
Respiratory depression (especially with opioids/alcohol)	Discontinue; supportive care; flumazenil if severe (use with caution)
Paradoxical reactions (agitation, aggression, hostility, disinhibition)	Discontinue immediately; more common in elderly and children
Suicidal ideation (in depressed patients)	Close monitoring; psychiatric evaluation
Seizures (on abrupt discontinuation)	Hospitalisation may be required; reinstitute benzodiazepine and taper slowly
Severe hypotension	Supportive care; IV fluids
Angioedema (rare)	Discontinue permanently; emergency management

Monitoring requirements

Timing	Parameters
Baseline	Psychiatric assessment (anxiety severity, suicidal risk), substance use history, hepatic function (if impairment suspected), respiratory function
After initiation (1–2 weeks)	Sedation level, efficacy, behavioural changes, signs of dependence
Long-term (if continued)	Reassess need for continuation every 2–4 weeks; monitor for tolerance, dependence, cognitive impairment
On discontinuation	Taper over 2–4 weeks minimum (longer if prolonged use); monitor for withdrawal symptoms (anxiety, insomnia, tremor, seizures)

Brands in India

Restyl™ (Cipla) — 0.25 mg, 0.5 mg, 1 mg tablets
Alprax™ (Torrent) — 0.25 mg, 0.5 mg, 1 mg tablets
Trika™ (Unichem) — 0.25 mg, 0.5 mg tablets
Alzolam™ (Micro Labs) — 0.25 mg, 0.5 mg, 1 mg tablets
Zolax™ (Sun Pharma) — 0.25 mg, 0.5 mg tablets
Anxit™ (Micro Labs) — 0.25 mg, 0.5 mg tablets
Alprazolam SR / XR (various) — extended-release formulations

Fixed-Dose Combinations (FDCs):

Alprazolam + Propranolol (e.g., Inderal Plus) — available but use with caution
FDCs with antidepressants exist but are not routinely recommended outside specialist psychiatry

Price range (INR)

0.25 mg tablet	₹1.50–₹3.00 per tablet
0.5 mg tablet	₹2.00–₹5.00 per tablet
1 mg tablet	₹3.00–₹7.00 per tablet
2 mg tablet	₹5.00–₹10.00 per tablet
Extended-release	₹5.00–₹12.00 per tablet

Regulatory: Not listed under NLEM 2022; not under NPPA price control; prices vary by brand and region

Clinical pearls

Not first-line for chronic anxiety — SSRIs (escitalopram, sertraline) are preferred for long-term anxiety management; reserve alprazolam for short-term use or acute exacerbations
Short half-life issue — Rebound anxiety and interdose withdrawal common; consider extended-release formulation or longer-acting benzodiazepine (clonazepam) for panic disorder if frequent dosing problematic
Taper slowly on discontinuation — Reduce by 0.25–0.5 mg every 3–5 days; withdrawal seizures can occur with abrupt cessation after >2 weeks of regular use
Elderly prescribing — Start very low (0.25 mg), titrate slowly; strongly associated with falls, fractures, and cognitive decline; avoid if possible
Dependence risk counselling — Warn patients about dependence with use beyond 2–4 weeks; avoid in patients with substance use history
Driving and machinery warning — Mandatory counselling; impairment may persist even without subjective sedation

Version

RxIndia v1.0 — 07 May 2025

Reference

CDSCO Product Information
Indian Pharmacopoeia (IP)
API Textbook of Medicine
AIIMS Psychiatry Prescribing Protocols
Indian Psychiatric Society Consensus Statements
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Harrison's Principles of Internal Medicine
WHO Essential Medicines List (supportive reference for paediatric considerations)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.